Having previously established that APE1’s redox function drives PDAC progression using C65A redox-deficient mutants (25), we investigated whether selective impairment of APE1’s endonuclease activity similarly affects tumor growth and metastatic potential in vivo. The gene discussed is APEX1; the disease is neoplasm.